To identify specific cancers where ABT-SLCs are more likely to be under positive selection, we stratified the proportion of tumour samples carrying at least one ABT-SLC somatic mutation by TCGA cohort, then plotted against the cohort’s median tumour mutation burden with linear model fitting (Fig. 2a). This evidence concerns the gene CCL21 and cancer.